Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports.
10.11817/j.issn.1672-7347.2018.11.018
- Author:
Shuang QU
1
,
2
;
Lisheng LIAO
1
,
2
;
Ying XIE
1
,
2
;
Zhihai ZHENG
1
,
2
;
Biyun CHEN
1
,
2
Author Information
1. Department of Hematology, Fujian Provincial Hospital
2. Provincial Clinical Medicine College, Fujian Medical University, Fuzhou 350001, China.
- Publication Type:Case Reports
- MeSH:
Antineoplastic Agents;
therapeutic use;
Antineoplastic Combined Chemotherapy Protocols;
Bortezomib;
therapeutic use;
Brain Neoplasms;
drug therapy;
genetics;
pathology;
Gene Deletion;
Humans;
Multiple Myeloma;
drug therapy;
genetics;
pathology;
Prognosis;
Treatment Outcome;
Tumor Suppressor Protein p53;
genetics
- From:
Journal of Central South University(Medical Sciences)
2018;43(11):1272-1275
- CountryChina
- Language:Chinese
-
Abstract:
We report two rare cases of multiple myeloma (MM) with dural intracranial disease and TP53 deletion. The two patients presented with skull lytic lesion and dural involvement of myeloma. The association between intracranial involvement in MM and TP53 deletion has not been determined. The two patients received bortezomib-based intensive induction and got good response, just as that reported in literature. MM presenting with dural intracranial disease and TP53 deletion at diagnosis is associated with poor outcome. Multi-drug regime containing bortezomib followed by autologous or allogeneic stem cell transportation would improve the prognosis.
